Earlier this month, Amgen announced that the FDA approved UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia ...
(RTTNews) - Amgen (AMGN) announced that the U.S. Food and Drug Administration has granted full approval to IMDELLTRA (tarlatamab-dlle) for the treatment of adult patients with extensive stage small ...
Underscores IMDELLTRA as a Recognized Standard of Care Treatment for Patients With Extensive Stage Small Cell Lung Cancer That Has Progressed THOUSAND OAKS, Calif., Nov. 19, 2025 /PRNewswire/ -- Amgen ...
Results showed tarlatamab significantly reduced the risk of death by 40% vs standard of care treatment (HR, 0.60 [95% CI, 0.47-0.77]; P .001). The Food and Drug Administration (FDA) has granted ...
Global Confirmatory Phase 3 DeLLphi-304 Trial Showed IMDELLTRA Reduced Risk of Death by 40% Compared to Chemotherapy Underscores IMDELLTRA as a Recognized Standard of Care Treatment for Patients With ...
Amgen (AMGN) just received full approval from the FDA for IMDELLTRA in treating adult patients with extensive stage small cell lung cancer after platinum-based chemotherapy. The NCCN also updated ...
Amgen recently announced that the FDA granted full approval to IMDELLTRA (tarlatamab-dlle) for adults with extensive stage small cell lung cancer (ES-SCLC) who have progressed after platinum-based ...
THOUSAND OAKS, Calif. - The U.S. Food and Drug Administration has granted full approval to Amgen’s (NASDAQ:AMGN) IMDELLTRA for treating adult patients with extensive stage small cell lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback